Pharming Group N.V. (PHGUF)
USD 0.84
(0.0%)
USD 0.84
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 171.54 Million USD | 2.91% |
| 2022 | 166.69 Million USD | 3.16% |
| 2021 | 161.59 Million EUR | -0.38% |
| 2020 | 162.21 Million EUR | 179.03% |
| 2019 | 58.13 Million EUR | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 98.62 Million EUR | 39.16% |
| 2016 | 70.87 Million EUR | 308.63% |
| 2015 | 17.34 Million EUR | 796.55% |
| 2014 | 1.93 Million EUR | -28.99% |
| 2013 | 2.72 Million EUR | -27.87% |
| 2012 | 3.77 Million EUR | -15.11% |
| 2011 | 4.44 Million EUR | 4244.9% |
| 2010 | 102.4 Thousand EUR | -99.69% |
| 2009 | 33.27 Million EUR | -57.77% |
| 2008 | 78.78 Million EUR | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 2.08 Million EUR | 3490.88% |
| 2005 | 58.03 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 133.03 Million USD | -20.36% |
| 2024 Q3 | 95.41 Million USD | -4.47% |
| 2024 Q1 | 167.05 Million USD | -2.54% |
| 2023 Q1 | 170.39 Million USD | 2.22% |
| 2023 Q3 | 163.98 Million USD | -3.61% |
| 2023 Q2 | 170.13 Million USD | -0.16% |
| 2023 FY | 171.54 Million USD | 2.91% |
| 2023 Q4 | 171.4 Million USD | 4.52% |
| 2022 Q3 | 139.18 Million USD | -6.59% |
| 2022 Q4 | 166.69 Million USD | 19.77% |
| 2022 FY | 166.69 Million USD | 3.16% |
| 2022 Q1 | 157.78 Million USD | -2.41% |
| 2022 Q2 | 149 Million USD | -5.57% |
| 2021 Q2 | 170.38 Million EUR | 10.73% |
| 2021 Q3 | 164.66 Million EUR | -3.36% |
| 2021 Q4 | 161.68 Million EUR | -1.81% |
| 2021 FY | 161.59 Million EUR | -0.38% |
| 2021 Q1 | 153.88 Million EUR | -4.99% |
| 2020 Q1 | 140.36 Million EUR | 141.17% |
| 2020 FY | 162.21 Million EUR | 179.03% |
| 2020 Q4 | 161.95 Million EUR | 6.08% |
| 2020 Q3 | 152.67 Million EUR | 5.31% |
| 2020 Q2 | 144.97 Million EUR | 3.29% |
| 2019 Q4 | 58.2 Million EUR | -12.14% |
| 2019 Q1 | 80.25 Million EUR | -3.59% |
| 2019 Q2 | 74.6 Million EUR | -7.04% |
| 2019 FY | 58.13 Million EUR | 0.0% |
| 2019 Q3 | 66.24 Million EUR | -11.21% |
| 2018 Q3 | 90.4 Million EUR | -6.4% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | 83.24 Million USD | -7.92% |
| 2018 Q2 | 96.59 Million EUR | -0.31% |
| 2018 Q1 | 96.89 Million EUR | -1.76% |
| 2017 Q1 | 70.09 Million EUR | -1.11% |
| 2017 FY | 98.62 Million EUR | 39.16% |
| 2017 Q4 | 98.62 Million EUR | -5.03% |
| 2017 Q3 | 103.84 Million EUR | 0.32% |
| 2017 Q2 | 103.51 Million EUR | 47.69% |
| 2016 Q3 | 17.12 Million EUR | -3.22% |
| 2016 Q1 | 17.46 Million EUR | 0.7% |
| 2016 Q2 | 17.69 Million EUR | 1.33% |
| 2016 Q4 | 70.87 Million EUR | 313.79% |
| 2016 FY | 70.87 Million EUR | 308.63% |
| 2015 FY | 17.34 Million EUR | 796.55% |
| 2015 Q3 | 18.37 Million EUR | 1381.41% |
| 2015 Q4 | 17.34 Million EUR | -5.61% |
| 2015 Q2 | 1.24 Million EUR | -5.87% |
| 2015 Q1 | 1.31 Million EUR | -31.88% |
| 2014 FY | 1.93 Million EUR | -28.99% |
| 2014 Q4 | 1.93 Million EUR | -0.87% |
| 2014 Q3 | 1.95 Million EUR | -13.93% |
| 2014 Q2 | 2.26 Million EUR | 1.46% |
| 2014 Q1 | 2.23 Million EUR | -17.97% |
| 2013 Q2 | 11.74 Million EUR | -25.67% |
| 2013 Q4 | 2.72 Million EUR | -58.17% |
| 2013 FY | 2.72 Million EUR | -27.87% |
| 2013 Q3 | 6.51 Million EUR | -44.54% |
| 2013 Q1 | 15.8 Million EUR | 318.35% |
| 2012 Q3 | 3.93 Million EUR | 0.0% |
| 2012 Q1 | 8.23 Million EUR | 85.07% |
| 2012 Q4 | 3.77 Million EUR | -4.06% |
| 2012 FY | 3.77 Million EUR | -15.11% |
| 2011 FY | 4.44 Million EUR | 4244.9% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q1 | - EUR | -100.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | 4.44 Million EUR | 0.0% |
| 2010 Q2 | 42.09 Million EUR | -13.55% |
| 2010 FY | 102.4 Thousand EUR | -99.69% |
| 2010 Q1 | 48.68 Million EUR | 46.34% |
| 2010 Q4 | 102.4 Thousand EUR | -99.32% |
| 2010 Q3 | 15.14 Million EUR | -64.01% |
| 2009 FY | 33.27 Million EUR | -57.77% |
| 2009 Q4 | 33.27 Million EUR | 0.0% |
| 2008 FY | 78.78 Million EUR | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2006 FY | 2.08 Million EUR | 3490.88% |
| 2005 FY | 58.03 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -316.341% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -4061.737% |
| SQZ Biotechnologies Company | 27.47 Million USD | -524.459% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -295.511% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -476.29% |
| Mesoblast Limited | 118.7 Million USD | -44.519% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -17990.293% |
| Genus plc | 233.1 Million USD | 26.407% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -5754.003% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -12667.717% |
| Marizyme, Inc. | 18.71 Million USD | -816.496% |
| ContraFect Corporation | 2.88 Million USD | -5854.356% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -22772.667% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -126513.623% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -11760.8% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -7275.25% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -2931.713% |
| MultiCell Technologies, Inc. | 202.58 USD | -84680026.37% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -198.396% |
| EV Biologics, Inc. | 1.49 Million USD | -11376.493% |
| Q BioMed Inc. | 4.1 Million USD | -4073.864% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -418.247% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -27126.037% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -13865.357% |
| Biomind Labs Inc. | 735.54 Thousand USD | -23222.258% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -1219.882% |
| Skye Bioscience, Inc. | 4.61 Million USD | -3616.904% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -19216.738% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -121117.796% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -2821.859% |
| IMV Inc. | 28.88 Million USD | -493.912% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -666897.162% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -7495.928% |
| GB Sciences, Inc. | 1.75 Million USD | -9650.714% |
| Alpha Cognition Inc. | 1.22 Million USD | -13956.779% |
| HST Global, Inc. | 98.31 Thousand USD | -174377.975% |
| CSL Limited | 12.18 Billion USD | 98.592% |
| Halberd Corporation | 150 Thousand USD | -114263.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -17117.551% |
| Resverlogix Corp. | 6.49 Million USD | -2542.813% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -35825.654% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -67016.733% |
| argenx SE | 20 Million USD | -757.725% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -276.525% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -6233.105% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1677601.711% |
| Genscript Biotech Corporation | 417.73 Million USD | 58.935% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -85409.132% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -7054.493% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -74715.409% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -153.604% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -5568.677% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -47589.806% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -743.885% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -115298.846% |
| BioStem Technologies, Inc. | 4.71 Million USD | -3541.049% |
| ONE Bio Corp. | 19.71 Million USD | -770.123% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -68468.082% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -68871.132% |
| Agentix Corp. | 50 Thousand USD | -342990.0% |
| LadRx Corporation | 33.6 Thousand USD | -510359.442% |
| Cell Source, Inc. | 9.25 Million USD | -1753.704% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -22585.016% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -22585.016% |
| NovAccess Global Inc. | 2.19 Million USD | -7697.925% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -2325.415% |
| Itoco Inc. | 228.37 Thousand USD | -75014.832% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -81210.582% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -3342.605% |
| Kadimastem Ltd | 891.22 Thousand USD | -19148.204% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -42588.92% |
| CytoDyn Inc. | 30.07 Million USD | -470.372% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -35322.397% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -48655.567% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -2093.681% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -139936.735% |
| Rebus Holdings, Inc. | 310 Thousand USD | -55237.097% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -3522.699% |
| International Stem Cell Corporation | 4.17 Million USD | -4005.912% |
| Bioxytran, Inc. | 1.92 Million USD | -8811.429% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -274754.598% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -7765.789% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1962.831% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -1898.195% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -10928.436% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -63909.328% |
| Neutra Corp. | 54.15 Thousand USD | -316660.839% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -9274.044% |
| PureTech Health plc | 25.51 Million USD | -572.409% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -13912.527% |
| IXICO plc | 472.02 Thousand USD | -36242.509% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -1006.671% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -175.517% |
| CSL Limited | 12.18 Billion USD | 98.592% |
| Cellectis S.A. | 92.77 Million USD | -84.901% |